Glenmark Pharmaceuticals has announced its financial results for the fourth quarter and full year ended March 2025, highlighting a solid profit growth despite increasing interest costs. The company’s performance was driven by robust sales across its key markets and a strong product pipeline.
Revenue for the quarter ended March 2025 stood at ₹3,483.6 crore, representing a 13.4% year-over-year (YoY) growth. For the full year, revenue was ₹12,853.1 crore, up 12.1% YoY. The company’s operating profit (EBITDA) for the quarter was ₹731.4 crore, with a margin of 21%, while full-year EBITDA reached ₹2,631.4 crore.
Net profit for the quarter ended March 2025 was ₹356.2 crore, a significant increase of 25.5% YoY. However, the company’s interest costs rose to ₹133.8 crore during the quarter, up from ₹93.8 crore in the same period last year. This increase was primarily due to higher borrowing costs and an expansion of the company’s debt.
Glenmark’s formulations business, which accounts for the majority of its revenue, grew 14.1% YoY in the fourth quarter, driven by strong sales in the United States, Europe, and India. The company’s US business, in particular, showed significant growth, with revenue increasing by 23.1% YoY.
The company’s research and development (R&D) expenses for the quarter were ₹245.8 crore, representing 7.1% of revenue. Glenmark has a strong pipeline of products under development, with several new drug applications (NDAs) and abbreviated new drug applications (ANDAs) filed in various markets.
Glenmark’s management expressed confidence in the company’s growth prospects, citing a robust product pipeline, expanding global presence, and a strong balance sheet. The company is focused on investing in R&D and expanding its presence in emerging markets to drive long-term growth.
Overall, Glenmark Pharmaceuticals’ fourth-quarter and full-year results demonstrated the company’s ability to deliver strong profit growth despite rising interest costs. With a solid product pipeline and expanding global presence, the company is well-positioned for long-term success in the pharmaceutical industry. As the company continues to invest in R&D and expand its presence in emerging markets, investors will be closely watching its future performance to assess the sustainability of its growth trajectory.